RiteMED Alendronic Acid Indications/Uses

Treatment of Osteoporosis in Postmenopausal Women: Alendronic Acid is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, Alendronic Acid increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures).
Prevention of Osteoporosis in Postmenopausal Women: Alendronic Acid is indicated for prevention of postmenopausal osteoporosis.
Treatment to Increase Bone Mass in Men with Osteoporosis: Alendronic Acid is indicated for the treatment to increase bone mass in men with osteoporosis.
Treatment for Glucocorticoid-Induced Osteoporosis: Alendronic Acid is indicated for treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density.
Treatment of Paget's disease of Bone: Alendronic Acid is indicated for the treatment of Paget's disease of bone in men and women. Treatment is indicated in Paget's disease of bone who have alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease.
Important Limitations of Use: The optimal duration of use has not been determined. The safety and effectiveness of Alendronic Acid for the treatment of osteoporosis are based on clinical data of four years duration. All the patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk of fracture should be considered for drug continuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.